Everest Medicines Limited announced that substantial shareholder CBC Group, led by non-executive director and honorary chairman Wei Fu, purchased 600,500 ordinary shares on the open market between 20 May and 21 May 2026. The transaction was executed at an average price of HK$31.91 per share, for a total consideration of approximately HK$19.20 million.

Including these latest trades, CBC Group together with the company’s directors have accumulated more than 3.06 million Everest Medicines shares since December 2025, deploying over HK$113.80 million in aggregate.

The board stated that the continued share purchases demonstrate firm confidence in Everest Medicines’ long-term prospects and development. Management indicated that additional increases in shareholding may be considered, subject to compliance with applicable regulations.

The company reiterated that shareholders and potential investors should exercise caution when dealing in Everest Medicines’ securities.